CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer

<div>A quantitative method to forecast the probability of OC patients surviving one, three, or five years after their diagnosis. (a) A nomogram that estimates the likelihood that OC patients will be alive at 1, 3, and 5 years after diagnosis. (b) The calibration plots of the nomogram, which are used to forecast the likelihood of having OS at 1, 3, and 5 years.</div>

Mediators of Inflammation

fig5

Figure 5

Figure 5: CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer 